Skip Ribbon Commands
Skip to main content
Clin Asst Prof Chua Lee Min Kevin

Clin Asst Prof Chua Lee Min Kevin

Senior Consultant

National Cancer Centre Singapore

Specialty: Radiation Oncology

Clinical Interest: Neuro-Oncology, Thoracic-Oncology

Conditions Treated by this Doctor:
Brain cancer, Lung Cancer.

Clinical Appointments

  • Senior Consultant Division of Radiation Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Clinical Asst Professor at Duke-NUS Medical School


Dr Kevin Chua is a clinician investigator in the Precision Radiation Oncology Programme. He earned his medical degree with distinction from King’s College London School of Medicine. As a recipient of the Health Manpower Development Plan fellowship award, he completed fellowships in clinical oncology at the University College London Hospital and National Hospital for Neurology and Neurosurgery. He currently serves as co-chair of the neuro-oncology service and leads the stereotactic radiosurgery service for the treatment of brain and spine metastases. In recognition of his efforts, he was awarded the Singapore Health Quality Service Award. He also serves on the Advanced Radiation Technology committee in the International Association for the Study of Lung Cancer (IASLC) and is an associate editor for the British Journal of Radiology.

His research interests lie in the discovery of biomarker signatures for radio-resistance. He has published in high-impact journals including the International Journal of Radiation Oncology, Biology, Physics, Journal of Thoracic Oncology, Annals of Oncology and JAMA Oncology and his work has led to presentations at international scientific meetings of the International Stereotactic Radiosurgery Society (ISRS), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Wolfsburg Meeting on Molecular Radiation Biology/ Oncology and American Society for Radiation Oncology (ASTRO). Of note, he received the Conquer Cancer Foundation ASCO Merit Award in recognition of his top-ranked abstract on his work profiling the systemic immune landscape following radiotherapy.


  • MBBS (London)
  • FRCR (Clinical Oncology, UK)

Professional Appointments and Committee Memberships

  • Co-chair, Neuro-oncology cancer service line development workgroup
  • Member, Advanced Radiation Technology (ART) Committee, International Association for the Study of Lung Cancer (IASLC)
  • Fellow, The Royal College of Radiologists (RCR)
  • Abstract reviewer (CNS), ASTRO Annual Meeting
  • Member, Asian Society for Neuro-Oncology (ASNO)


  • Singapore Health Quality Service Award 2019
  • Conquer Cancer Foundation ASCO Merit Award 2018
  • Health manpower development fellowship award 2012

Research Interests

  • Precision radiotherapy techniques for the delivery of ablative treatments for central nervous system, spine and thoracic malignancies
  • Development of biomarker signatures for radioresistance


  • High-dimensional characterization of the systemic immune landscape informs on synergism between radiotherapy and immune checkpoint blockade. Kevin L.M. Chua, et al. Int J Radiat Oncol Biol Phys. 2020. Epub ahead of print.
  • Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer. Tan WL, Chua KLM (co-first author), et al. J Thorac Oncol. 2020 Mar; 15(3):324-343. doi: 10.1016/j.jtho.2019.10.022.
  • Response evaluation after stereotactic ablative radiotherapy for localized non-small cell lung cancer: equipoise of available resource and accuracy. Andre G Gouveia, Osbert C Zalay, Kevin LM Chua, Fabio Ynoe Moraes. Br J Radiol. 2019 Dec. doi: 10.1259/bjr.20190647. Epub ahead of print.
  • Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. K. Park, J. Vansteenkiste, K.H. Lee, G. Pentheroudakis, C. Zhou, K. Prabhash, T. Seto, P.J. Voon, D.S.W. Tan, J.C.H. Yang, J. Wang, K. Govind Babu, Y. Nakayama, A. Alip, K.L.M. Chua, et al. Ann Oncol. 2020 Feb; 31(2):191-201. doi: 10.1016/j.annonc.2019.10.026.
  • Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review and Synthesis for the Modern Oncologist. Rachel M Glicksman, Michael Tjong, Wellington F P Neves-Junior, Daniel E Spratt, Kevin L.M. Chua, et al. 2020 Jan; 6(4):567-577. doi: 10.1001/jamaoncol.2019.5351.
  • Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. Chu PL, Shihabuddeen WA, Low KP, Poon DJJ, Ramaswamy B, Liang ZG, Nei WL, Chua KLM, et al. Photodiagnosis Photodyn Ther. 2019 Sep; 27:367-374. doi: 10.1016/j.pdpdt.2019.06.008.
  • Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate. Gail Wan Ying Chua, Kevin Lee Min Chua. Thorac Cancer. 2019 Oct; 10(10):1857-1867. doi: 10.1111/1759-7714.13160.
  • Are heart doses associated with survival in patients with non-small cell lung cancer who received post-operative thoracic radiotherapy?: A national population based study. Lee CC, Chua GWY, Zheng H, Soon YY, Foo LL, Thiagarajan A, Yap SP, Siow TR, Ng WL, Chua KLM, et al. Medicine (Baltimore). 2019 Aug; 98(35):e17020. doi: 10.1097/MD.0000000000017020.
  • Coming of age of bevacizumab in the management of radiation-induced cerebral necrosis. Melvin L.K. Chua, Kevin L.M. Chua, Joseph T.S. Wee. Ann Transl Med. 2019 Apr; 7(7):155. doi: 10.21037/atm.2019.03.17.
  • Intra- and Inter-patient Comparisons of DNA Damage Response Biomarkers in Nasopharynx Cancer (NPC): Analysis of NCC0901 Randomised Controlled Trial of Induction Chemotherapy in Locally Advanced NPC. Kevin Lee Min Chua, et al. BMC Cancer. 2018 Nov 12; 18(1):1095. doi: 10.1186/s12885-018-5005-2.

Research Trials